N/A
Completed N=165
The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids
Source: ClinicalTrials.gov NCT00951912 ↗Enrolled (actual)
165
Serious AEs
0.0%
Results posted
Oct 2012
Primary outcomePrimary: Percentage Change in Fasting Plasma Glucose — -1.80; -1.00; -4.89 percentage of change — p=<0.05
Summary
Many studies showed that soy foods or soy isoflavones can lower the risk of cardiovascular disease (CVD), osteoporosis and some cancers, but few human studies assessed effects of purified isoflavone components (genistein and daidzein) on glucose metabolism. This double-blinded, randomized, placebo-controlled trial will examine the effects of purified genistein and daidzein on glucose metabolism in prediabetic or diabetic women. One hundred and eighty eligible women age 30-70 years(without any treatment of diabetic drugs) will be recruited and randomly allocated into the following three arms: Placebo (10g isolated soy protein, ISP); Genistein (10g ISP + 50mg genistein); Daidzein (10g ISP + 50mg daidzein) per day for 6 mo. Fasting glucose, lipids, insulin, inflammation marks and post-load for glucose and insulin will be determined at 0, 3th, and 6th month. Changes in these indices will be compared among the three groups.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Change in Fasting Plasma Glucose |
-1.80; -1.00; -4.89 | <0.05 sig |
| PRIMARY Percentage Change in 120-minutes Postload Plasma Glucose |
-4.90; -3.13; -5.59 | <0.05 sig |
| PRIMARY Percentage Change in HbA1C |
-1.38; -1.37; -1.30 | <0.05 sig |
| PRIMARY Percentage Change in AUC of Glucose |
-6.23; -3.27; -5.24 | <0.05 sig |
| PRIMARY Percentage Change in Fasting Plasma Insulin |
25.27; 21.41; 6.06 | <0.05 sig |
| PRIMARY Percentage Change in HOMA-IR |
22.83; 21.60; -0.22 | <0.05 sig |
| PRIMARY Percentage Change in QUICKI |
2.32; 0.18; 6.29 | <0.05 sig |
| PRIMARY Percentage Change in Total Cholesterol |
2.85; -0.59; -0.64 | <0.05 sig |
| PRIMARY Percentage Change in Triglyceride |
5.93; 3.43; -1.56 | <0.05 sig |
| PRIMARY Percentage Change in High Density Lipoprotein Cholesterol |
3.18; 1.36; 2.15 | <0.05 sig |
| PRIMARY Percentage Change in Low Density Lipoprotein Cholesterol |
1.08; -0.93; 1.86 | <0.05 sig |
| SECONDARY Total Urinary Isoflavones |
8.538; 25.818; 15.467 | <0.05 sig |
| SECONDARY Urinary Daidzein |
3.34; 11.80; 3.73 | <0.05 sig |
| SECONDARY Urinary Genistein |
1.32; 1.89; 6.54 | <0.05 sig |
| SECONDARY Total Energy Intake at Follow-up |
1575; 1473; 1579 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- Chinese women aged 30-70 y
- Fasting glucose >=5.6 mmol/l; post-load glucose >=7.8 mmol/l
Exclusion Criteria
- Diabetes renal diseases
- Confirmed CVD, chronic liver,kidney diseases,Thyroid disease
- Medications affecting glucose or lipid metabolism
Data sourced from ClinicalTrials.gov (NCT00951912). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.